Da Qing Offspring Study

April 27, 2025 updated by: Bo Zhang, China-Japan Friendship Hospital
This is an observational study tracking families and offspring of three cohorts from the 1986 Da Qing study: newly diagnosed diabetes, impaired glucose tolerance, and normoglycemia groups. Based on the original participants, the study will further include their spouses, first to third-generation offspring, and spouses of the offspring. General demographic information will be collected, and anthropometric measurements will be refined. A structured questionnaire will be used to gather disease history, family history of diabetes, and related information. Comprehensive diabetes-related laboratory screening and complication assessments will be conducted. A standardized biobank will be established, including blood and urine samples from the Da Qing Offspring Study, to support future research on epigenetics, metabolomics, and other mechanisms.

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

5000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Beijing
      • Beijing, Beijing, China, 100029
        • China-Japan Friendship Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Original subjects and spouses (70-90 years old), N=576+576=1152; First generation (50-70 years old), based on an average of 3 children per family, N=576*3=1728; The marriage rate of first generation is 90%, and the spouses N=1555; Second generation (25-45 years old), based on 90% of families having children, with an average of 1 child per family, N=1555*90%*1=1400; The marriage rate of second generation is 70%, and the spouses N=1400*70%=980; Third generation (1-20 years old), based on 80% of families having children, with an average of 1 child per family, N=980*80%*1=784; Based on the follow-up rate of 70%, the total number of people is about 5,000.

Description

Inclusion Criteria:

  • Spouses of the original Daqing diabetes Prevention Research Population (IGT), offspring 1 to 3 generations, and offspring spouses were included in the study, without special restrictions on subjects' gender, age, basic disease status, etc。
  • Conduct a death agent investigation for some deceased members.

Exclusion Criteria:

▪People who are unwilling to participate in this study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Lifestyle intervention subjects and offspring group
The subjects who received lifestyle intervention in the original Daqing Diabetes Prevention Study, their spouses, children 1 to 3, and spouses of their offspring were included in the study.
Behavioral: Lifestyle interventions

Dietary intervention: 30kcal energy intake per kilogram of body weight per day, increase vegetable intake, control sugar and alcohol intake, encourage overweight and obese people to lose weight, lose 0.5-1kg per month until the weight reaches the target.

Exercise intervention: Appropriate physical activity in spare time, 30-40 minutes per day, 5 times a week.
Control group subjects and offspring
The subjects who did not received lifestyle intervention in the original Daqing Diabetes Prevention Study, their spouses, children 1 to 3, and spouses of their offspring were included in the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cumulative incidence rate of diabetes
Time Frame: Through study completion, an average of about 1.5 years
This study statistically analyzed the cumulative incidence rate of diabetes at the end of the study through interview, medical record review, physical examination
Through study completion, an average of about 1.5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
weight
Time Frame: Through study completion, an average of about 1.5 years
The subject's weight is recorded and the results are reported in kilograms.
Through study completion, an average of about 1.5 years
waist circumference
Time Frame: Through study completion, an average of about 1.5 years
The subjects' waist circumference was recorded and the waist circumference results were reported in centimeters.
Through study completion, an average of about 1.5 years
Height
Time Frame: Through study completion, an average of about 1.5 years
The subject's height was recorded, and the results were recorded in centimeters.
Through study completion, an average of about 1.5 years
Exercise frequency and intensity
Time Frame: Through study completion, an average of about 1.5 years
The subjects' daily exercise frequency and intensity were recorded.
Through study completion, an average of about 1.5 years
Coronary heart disease incidence
Time Frame: Through study completion, an average of about 1.5 years
This study statistically analyzed the incidence of coronary heart disease at the end of the study through interview, medical record review, physical examination
Through study completion, an average of about 1.5 years
all-cause deaths
Time Frame: Through study completion, an average of about 1.5 years
This study counted all-cause deaths at the end of the study through death certificate, medical record review, family interview
Through study completion, an average of about 1.5 years
incidence of diabetic peripheral neuropathy
Time Frame: Through study completion, an average of about 1.5 years
This study statistically analyzed the incidence of diabetic peripheral neuropathy at the end of the study through interview, medical record review, physical examination
Through study completion, an average of about 1.5 years
other cause mortality
Time Frame: Through study completion, an average of about 1.5 years
This study statistically analyzed other cause mortality at the end of the study through death record, medical record review, family interview
Through study completion, an average of about 1.5 years
cardiovascular mortality rate
Time Frame: Through study completion, an average of about 1.5 years
This study statistically analyzed the cardiovascular mortality rate at the end of the study through death certificate, medical record review, family interview
Through study completion, an average of about 1.5 years
incidence of blindness
Time Frame: Through study completion, an average of about 1.5 years
This study statistically analyzed the incidence of blindness at the end of the study through interview, medical record review, physical examination
Through study completion, an average of about 1.5 years
Diabetic retinopathy incidence
Time Frame: Through study completion, an average of about 1.5 years
This study statistically analyzed the incidence of diabetic retinopathy at the end of the study through interview, medical record review, physical examination
Through study completion, an average of about 1.5 years
Diabetic nephropathy incidence
Time Frame: Through study completion, an average of about 1.5 years
This study statistically analyzed the incidence of diabetic nephropathy at the end of the study through interview, medical record review, physical examination
Through study completion, an average of about 1.5 years
Peripheral vascular disease incidence
Time Frame: Through study completion, an average of about 1.5 years
This study statistically analyzed the incidence of peripheral vascular disease at the end of the study through interview, medical record review, physical examination
Through study completion, an average of about 1.5 years
Heart failure incidence
Time Frame: Through study completion, an average of about 1.5 years
This study statistically analyzed the incidence of heart failure at the end of the study through interview, medical record review, physical examination
Through study completion, an average of about 1.5 years
Stroke incidence
Time Frame: Through study completion, an average of about 1.5 years
This study statistically analyzed the incidence of stroke at the end of the study through interview, medical record review, physical examination
Through study completion, an average of about 1.5 years
dietary habits
Time Frame: Through study completion, an average of about 1.5 years
The subjects' eating habits and dietary preferences were assessed through patient interviews.
Through study completion, an average of about 1.5 years
health-related quality of life
Time Frame: Through study completion, an average of about 1.5 years
The EuroQol questionnaire or health status questionnaire was administered through patient interviews to assess the subjects' health-related quality of life.
Through study completion, an average of about 1.5 years
blood pressure
Time Frame: Through study completion, an average of about 1.5 years
During the visit, the subjects' systolic and diastolic blood pressures were measured at rest by physical examination. The measurements were performed twice and the average was taken.
Through study completion, an average of about 1.5 years
blood sugar
Time Frame: Through study completion, an average of about 1.5 years
Blood samples were collected from the subjects at 1 hour and 2 hours after the steamed bread meal when they were fasting. The blood samples were used to test blood sugar levels and blood lipids, including total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol.
Through study completion, an average of about 1.5 years
blood lipid
Time Frame: Through study completion, an average of about 1.5 years
Venous blood was collected from the subjects in a fasting state. The blood samples were used to test blood lipid status, including total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol.
Through study completion, an average of about 1.5 years
skin AGE
Time Frame: Through study completion, an average of about 1.5 years
The skin AGE of the subjects was measured by physical examination. After cleaning the inner skin of the forearm, the AGE Reader probe was gently placed on the skin surface, the excitation light was emitted and the fluorescence intensity was recorded. The results were repeated 3 times and the average value was taken.
Through study completion, an average of about 1.5 years
Tidal Volume
Time Frame: Through study completion, an average of about 1.5 years
The subjects were assessed for Tidal Volume, which reflects the ventilation efficiency in the basic breathing state. Tidal Volume is measured in liters.
Through study completion, an average of about 1.5 years
Functional Residual Capacity
Time Frame: Through study completion, an average of about 1.5 years
Subjects were assessed for Functional Residual Capacity, which reflects lung capacity. Functional Residual Capacity is measured in liters.
Through study completion, an average of about 1.5 years
Forced Vital Capacity
Time Frame: Through study completion, an average of about 1.5 years
The subjects were assessed for Forced Vital Capacity, which reflects the overall ventilation capacity of the lungs. Forced Vital Capacity is measured in liters.
Through study completion, an average of about 1.5 years
Forced Expiratory Volume in 1 second
Time Frame: Through study completion, an average of about 1.5 years
The subjects were assessed for Forced Expiratory Volume in 1 second, which reflects respiratory reserve capacity. Forced Expiratory Volume in 1 second is measured in liters.
Through study completion, an average of about 1.5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

China-Japan Friendship Hospital

Collaborators

Daqing Oil Field Hospital

Investigators

  • Principal Investigator: Liping Yu, Doctor, China-Japan Friendship Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2025

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

April 16, 2025

First Submitted That Met QC Criteria

April 27, 2025

First Posted (Actual)

May 6, 2025

Study Record Updates

Last Update Posted (Actual)

May 6, 2025

Last Update Submitted That Met QC Criteria

April 27, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2022-NHLHCRF-YS-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus

Clinical Trials on Lifestyle interventions

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe